← Leaderboards
Kenneth G Lucas
University Of Alabama At Birmingham
$2,028,141
Attributed
$2,028,141
Total exposure
4
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $260.4K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
NIH$2,028,141 · 4
By mechanism
R01$1,164,510 · 2
R21$863,631 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Casey T Weaver$23,846,284
- Max D Cooper$23,641,392
- Troy D Randall$33,910,350
- Allan J Zajac$14,007,973
- Yingzi Cong$12,354,458
Others in their field
Top investigators on “Cytotoxic T Lymphocyte”
- Kent J. Weinhold · Duke University$45,701,691
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$34,242,475
- Douglas F Nixon · J. David Gladstone Institutes$33,075,518
- David I Watkins · George Washington University$27,012,765
- R. Brad Jones · Massachusetts Institute Of Technology$23,891,231
- Rafi Ahmed · Emory University$22,830,612
Research focus
Cytotoxic T LymphocyteEpstein Barr VirusHuman SubjectHomologous TransplantationVaccinia VirusPassive ImmunizationPolymerase Chain ReactionCytomegalovirusGraft Versus Host DiseaseHuman Therapy EvaluationCell LinePatient Oriented ResearchNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer ChemotherapyNeoplasm /Cancer VaccineT Cell ReceptorClinical ResearchImmunosuppressiveFlow CytometryHodgkin'S DiseaseArtificial ImmunosuppressionCombination Cancer TherapyHistocompatibility AntigensMicroorganism Immunology
Grant awards (10)
Virus Specific CTL following T cell depleted SCT$238,491
R01 · FY2009 · CA · contact PI
Virus Specific CTL following T cell depleted SCT$238,992
R01 · FY2008 · CA · contact PI
Virus Specific CTL following T cell depleted SCT$246,626
R01 · FY2006 · CA · contact PI
Virus Specific CTL following T cell depleted SCT$260,404
R01 · FY2005 · CA
Immunotherapy for EBV Positive Hodgkin's Disease$251,125
R21 · FY2002 · CA
Immunotherapy for EBV Positive Hodgkin's Disease$39,463
R21 · FY2002 · CA
Immunotherapy for EBV Positive Hodgkin's Disease$290,588
R21 · FY2001 · CA
IMMUNOTHERAPY WITH CMV AND EBV SPECIFIC T LYMPHOCYTES$143,315
R21 · FY2001 · CA
ADOPTIVE IMMUNOTHERAPY FOR POSTTRANSPLANT EBV LYMPHOMA$179,997
R01 · FY2000 · CA
IMMUNOTHERAPY WITH CMV AND EBV SPECIFIC T LYMPHOCYTES$139,140
R21 · FY2000 · CA